Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for Israeli Healthcare Professionals only.

      pdd_banner_1
      pdd_banner_2
      pdd_banner_3
      pdd_banner_4
      Previous
      Next

      PRODUODOPA is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.1

      new banner 4
      icon-12-Weeks

      CLINICAL DATA

      PRODUODOPA efficacy and safety data from the 12- and 52-week studies.2,3

      View PRODUODOPA data
      icon-Infusion-site-events

      SAFETY

      Read safety information including adverse events for PRODUODOPA.

      View safety information
      icon-Most-frequent-aes v2

      DOSING AND ADMINISTRATION

      Learn about the dosing and administration of PRODUODOPA.

      View dosing and administration
      Dose calculator
      AbbVie Care

      References

      1. PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) prescribing information.
      2. Soileau MJ, et al. Lancet Neurol. 2022;21:1099–1109.
      3. Aldred J, et al. Neurol Ther. 2023 Aug 26. doi: 10.1007/5. s40120-023-00533.

      For Produodopa Prescribing Information click here

      IL-PRODD-240009. Date of preparation: July 2024.

      As part of ABBVIE CARE Produodopa patient support program,
      a professional call center is available: 

      Sunday through Thursday
      8:00-17:00

      052-8113004